Controlling the Drug Resistant TB Epidemic in India: Challenges & Implications
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.
Abstract
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.
참고문헌 (30)
- "Global tuberculosis report 2020"[URL]
- "India TB report 2020: national tuberculosis elimination programme annual report"[URL]
- Chatterjee S, "Drug-resistant tuberculosis: is India ready for the challenge?", BMJ Glob Health, 3, pp.e000971~ (2018)
- Chaudhuri AD, "Recent changes in guidelines on programmatic management of drug resistant tuberculosis in India 2019 : a paradigm shift in tuberculosis control", J Assoc Chest Physicians, 8, pp.53~63 (2020)
- "Standards for TB care in India" (2014)[URL]
- "Report of first national anti-tuberculosis drug resistance survey India (2014-16)"[URL]
- "Definitions and reporting framework for tuberculosis 2013 revision, updated December 2014 and January 2020"[URL]
- Arinaminpathy N, "The number of privately treated tuberculosis cases in India : an estimation from drug sales data", Lancet Infect Dis, 16, pp.1255~1260 (2016)
- Yellappa V, "Patients pathways to tuberculosis diagnosis and treatment in a fragmented health system : a qualitative study from a south Indian district", BMC Public Health, 17, pp.635~ (2017)
- Siddaiah A, "Tuberculosis notification in a private tertiary care teaching hospital in South India : a mixed-methods study", BMJ Open, 9, pp.e023910~ (2019)
- "More than half of India’s drug-resistant tb cases remain undetected" (2019)[URL]
- Prasad R, "Multidrug-resistant tuberculosis", rifampicin-resistant tuberculosis : principles of management, 2018, pp.35, 78~81
- Schito M, "Perspectives on advances in tuberculosis diagnostics, drugs, and vaccines", Clin Infect Dis, 61(Suppl 3), pp.S102~S118 (2015)
- Sharma K, "Xpert MTB", RIF ultra for the diagnosis of tuberculous meningitis:a diagnostic accuracy study from India, 2020, pp.125, 101990~
- Dorman SE, "Xpert MTB", RIF ultra for detection of mycobacterium tuberculosis and rifampicin resistance : a prospective multicentre diagnostic accuracy study, 2018, pp.18, 76~78
- "Tuberculosis diagnostics: molecular line-probe assay for the detection of resistance to second-line anti-TB drugs (SL-LPA)"[URL]
- "The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin" (2016)[URL]
- Lee DJ, "Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay : cost-effectiveness analysis for India’s public sector", PLoS One, 14, pp.e0218890~ (2019)
- "World Health Organization endorses truenat tests for initial diagnosis of tuberculosis and detection of rifampicin resistance"[URL]
- Cao Y, "Xpert MTB", XDR : a 10-color reflex assay suitable for point-ofcare settings to detect isoniazid, fluoroquinolone, and second-lineinjectable-drug resistance directly from mycobacterium tuberculosis-positive sputum, 2021, pp.59, e02314~e02320
- Pinto L, "Treatment of drug-resistant tuberculosis", Infect Drug Resist, 4, pp.129~135 (2011)
- Gualano G, "New antituberculosis drugs : from clinical trial to programmatic use", Infect Dis Rep, 8, pp.6569~ (2016)
- "WHO consolidated guidelines on drug-resistant tuberculosis treatment" (2019)[URL]
- Sharma SK, "What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?", Indian J Med Res, 149, pp.309~312 (2019)
- Saravu K, "Drug-resistant tuberculosis : progress towards shorter and safer regimens", Lung India, 36, pp.373~375 (2019)
- Mullerpattan JB, "Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India", Indian J Tuberc, 66, pp.87~91 (2019)
- Gupta R, "Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of M. tuberculosis isolates from Sahariya tribe of Madhya Pradesh India", J Infect Public Health, 12, pp.395~402 (2019)
- Udwadia ZF, "Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic", BMC Infect Dis, 19, pp.94~ (2019)
- Al-Ghafli H, "Drug-resistance profiling and transmission dynamics of multidrug-resistant Mycobacterium tuberculosis in Saudi Arabia revealed by whole genome sequencing", Infect Drug Resist, 11, pp.2219~2229 (2018)
- Dookie N, "Whole-genome sequencing to guide the selection of treatment for drug-resistant tuberculosis", Antimicrob Agents Chemother, 62, pp.e00574~e005718 (2018)